戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and hemodynamic improvement in patients with hypertrophic obstructive cardiomyopathy.
2 amic parameters in patients with symptomatic hypertrophic obstructive cardiomyopathy.
3  of patients with refractory symptoms due to hypertrophic obstructive cardiomyopathy.
4 minant of clinical symptoms in patients with hypertrophic obstructive cardiomyopathy.
5 r pacing in patients with severe symptoms of hypertrophic obstructive cardiomyopathy.
6 ptoms and decrease gradient in patients with hypertrophic obstructive cardiomyopathy.
7 d for all patients with severely symptomatic hypertrophic obstructive cardiomyopathy.
8 n the symptomatic treatment of patients with hypertrophic obstructive cardiomyopathy.
9  ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy.
10       These translated to 4 genes/1 ncRNA in hypertrophic obstructive cardiomyopathy, 131 genes/17 nc
11 ique differentially methylated regions: 5 in hypertrophic obstructive cardiomyopathy, 151 in dilated
12 rgoing alcohol septal ablation treatment for hypertrophic obstructive cardiomyopathy, a human model o
13 ies in patients with refractory, symptomatic hypertrophic obstructive cardiomyopathy and significant
14 ck-sinus syndrome, neurocardiogenic syncope, hypertrophic obstructive cardiomyopathy, and cardiac res
15 nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy at our instituti
16 s fingerprint is evident in 12 patients with hypertrophic obstructive cardiomyopathy before septal my
17 ow tract obstruction from aortic stenosis or hypertrophic obstructive cardiomyopathy but can also sug
18 emaker in patients with severely symptomatic hypertrophic obstructive cardiomyopathy can relieve symp
19                                      Because hypertrophic obstructive cardiomyopathy, dilated cardiom
20  to result in improved clinical outcomes for hypertrophic obstructive cardiomyopathy, dilated cardiom
21                                Patients with hypertrophic obstructive cardiomyopathy have left ventri
22 tflow tract (LVOT) velocity in patients with hypertrophic obstructive cardiomyopathy (HCM).
23 ow tract (LVOT) obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM) both acut
24                                              Hypertrophic obstructive cardiomyopathy (HOCM) is charac
25 ve (MV) surgery are unknown in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoin
26 uated in symptomatic pediatric patients with hypertrophic obstructive cardiomyopathy (HOCM) unrespons
27  evaluate follow-up results in patients with hypertrophic obstructive cardiomyopathy (HOCM) who under
28 sitive/phenotype negative), 10 patients with hypertrophic obstructive cardiomyopathy (HOCM), 10 patie
29 referred treatment for medication-refractory hypertrophic obstructive cardiomyopathy (HOCM), the proc
30 ) with septal myectomy (SM) for treatment of hypertrophic obstructive cardiomyopathy (HOCM).
31 tion and exercise tolerance in patients with hypertrophic obstructive cardiomyopathy (HOCM).
32  myocardial infarction (MI) in patients with hypertrophic obstructive cardiomyopathy (HOCM).
33 apy (surgical myectomy) for the treatment of hypertrophic obstructive cardiomyopathy (HOCM).
34 novel therapeutic strategy for patients with hypertrophic obstructive cardiomyopathy (HOCM).
35 dient and improves symptoms in patients with hypertrophic obstructive cardiomyopathy (HOCM).
36 surgical septal reduction therapy (NSRT) for hypertrophic obstructive cardiomyopathy (HOCM).
37 my with dual-chamber pacing in patients with hypertrophic obstructive cardiomyopathy (HOCM).
38 sessing response to therapy in patients with hypertrophic obstructive cardiomyopathy (HOCM).
39  a new promising treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM).
40 on is frequently responsible for symptoms in hypertrophic obstructive cardiomyopathy (HOCM).
41 phy with dynamic LVOT obstruction, mimicking hypertrophic obstructive cardiomyopathy in humans.
42 affirm the efficacy of surgical treatment of hypertrophic obstructive cardiomyopathy in patients who
43                                              Hypertrophic obstructive cardiomyopathy is an inherited
44 le HF patients encompassing causes including hypertrophic obstructive cardiomyopathy, ischemic cardio
45                                              Hypertrophic obstructive cardiomyopathy patients (N = 87
46                           Of 173 consecutive hypertrophic obstructive cardiomyopathy patients who und
47 s used for treatment of medically refractory hypertrophic obstructive cardiomyopathy patients with se
48 d a reduction in dynamic obstruction in most hypertrophic obstructive cardiomyopathy patients.
49                  A subgroup of patients with hypertrophic obstructive cardiomyopathy remain severely
50 wenty-one patients with severely symptomatic hypertrophic obstructive cardiomyopathy were entered int
51 ent relief of symptoms in most patients with hypertrophic obstructive cardiomyopathy who are severely
52 yzed for 65 patients 20 to 70 years old with hypertrophic obstructive cardiomyopathy who had surgical
53 dictive of clinical outcome in patients with hypertrophic obstructive cardiomyopathy who undergo sept
54                          Fifty patients with hypertrophic obstructive cardiomyopathy who underwent no
55 n polymerase chain reaction in patients with hypertrophic obstructive cardiomyopathy who were undergo
56 ective therapy for symptomatic patients with hypertrophic obstructive cardiomyopathy with persistence